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Leukocytosis correlates closely with cardiovas-
cular mortality. In the steady state, blood leu-
kocytes derive exclusively from bone marrow 
hematopoietic stem cells (HSCs). Supporting cells 
(Sugiyama et al., 2006; Ding et al., 2012; Ding 
and Morrison, 2013), including macrophages 
(Winkler et al., 2010; Chow et al., 2011), 
maintain the bone marrow HSC niche and 
regulate hematopoietic stem and progenitor cell 
(HSPC) activity by supplying various cytokines 
and retention factors. Systemic inflammation 
can stimulate extramedullary hematopoiesis in 
adult mice and humans. Splenic myelopoiesis 
supplies inflammatory monocytes to athero-
sclerotic plaques (Robbins et al., 2012) and the 
ischemic myocardium (Leuschner et al., 2012). In 
ischemic heart disease, HSPCs emigrate from the 
bone marrow, seed the spleen, and amplify 
leukocyte production (Dutta et al., 2012). 
Splenic HSPCs localize in the red pulp near the 
sinusoids in parafollicular areas (Kiel et al., 
2005). Likewise, after adoptive transfer of GFP+ 
HSPCs, GFP+ colonies populate the splenic red 
pulp of atherosclerotic ApoE/ mice (Robbins 
et al., 2012). During myocardial infarction (MI), 
proinflammatory monocytes derived from the 
spleen accelerate atherosclerotic progression 
(Dutta et al., 2012). Collectively, these data sug-
gest that splenic myelopoiesis has promise as a 
therapeutic target; however, the components of 
the splenic hematopoietic niche are incompletely 
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Splenic myelopoiesis provides a steady flow of leukocytes to inflamed tissues, and leukocy-
tosis correlates with cardiovascular mortality. Yet regulation of hematopoietic stem cell 
(HSC) activity in the spleen is incompletely understood. Here, we show that red pulp vascu-
lar cell adhesion molecule  (VCAM-)+ macrophages are essential to extramedullary 
myelopoiesis because these macrophages use the adhesion molecule VCAM- to retain 
HSCs in the spleen. Nanoparticle-enabled in vivo RNAi silencing of the receptor for macro-
phage colony stimulation factor (M-CSFR) blocked splenic macrophage maturation, reduced 
splenic VCAM- expression and compromised splenic HSC retention. Both, depleting mac-
rophages in CD69 iDTR mice or silencing VCAM- in macrophages released HSCs from the 
spleen. When we silenced either VCAM- or M-CSFR in mice with myocardial infarction or 
in ApoE/ mice with atherosclerosis, nanoparticle-enabled in vivo RNAi mitigated blood 
leukocytosis, limited inflammation in the ischemic heart, and reduced myeloid cell numbers 
in atherosclerotic plaques.
© 2015 Dutta et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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(Coelho et al., 2013). siCD115 was tested for in vivo silenc-
ing in the spleen, which has the highest siRNA concentration 
after systemic injection of nanoparticle carriers (Leuschner 
et al., 2011). Because the adult steady-state spleen harbors 
only a few HSPCs, we induced extramedullary hematopoi-
esis by treating mice with LPS. Mice then received injections 
of either siCD115 or control siRNA with an irrelevant se-
quence (siCON), both encapsulated in similar lipidoid deliv-
ery nanoparticles (Fig. 1 C). We found that two intravenous 
siCD115 injections reduced CD115 mRNA levels in splenic 
monocytes and macrophages by eightfold (Fig. 1 D) and led 
to a substantial (>75%) in vivo protein knockdown in leuko-
cytes (Fig. 1 E). Although the treatment did not significantly 
change body weight (Fig. 1 F), LPS-induced splenomegaly 
(Fig. 1 G) and splenic cell content (Fig. 1 H) fell significantly 
after siCD115 treatment. Moreover, siCD115 treatment 
significantly reduced serum IFN- levels (Fig. 1 I). Consis-
tently, CD115 knockdown reduced numbers of total blood 
monocytes and Ly-6chigh monocytes in LPS-challenged mice 
(Fig. 1, J and K).
M-CSFR knockdown decreases splenic HSPC numbers
Next, we enumerated splenic Lin Sca-1+ ckit+ CD48 
CD150+ HSCs, LSKs (Lin Sca-1+ ckit+ cells), and granulocyte-
macrophage progenitors (GMPs) (Lin Sca-1+ ckit+ CD16/
32high CD34high). The naive mouse spleen contained few 
hematopoietic stem and progenitor cells (HSCs, 666 ± 166; 
LSKs, 3,400 ± 1,030; GMPs, 1,300 ± 337 per spleen; Fig. 2, 
A and B). LPS treatment increased these numbers 30-, 39- 
and 33-fold, respectively. In parallel to the observation that 
RNAi curbed LPS-induced splenomegaly, we found that 
siCD115 treatment decreased splenic HSC, LSK, and GMP 
numbers significantly (Fig. 2, A and B). Similarly, M-CSFR 
knockdown reduced bone marrow HSPC numbers (Fig. 2 C). 
Because CD115 signaling contributes to macrophage survival 
(Shaposhnik et al., 2010), we investigated whether the recep-
tor has a similar effect on HSCs. CD115 knockdown did not 
affect HSC and LSK apoptosis in the bone marrow (Fig. 2 D) 
and spleen (Fig. 2 E).
Splenic niche maintenance requires M-CSFR signaling
To explore how M-CSFR knockdown reduced splenic HSPC 
numbers, we assessed HSPC proliferation using an in vivo 
BrdU incorporation assay, as M-CSF may facilitate cell prolif-
eration. However, BrdU incorporation by HSPCs did not 
differ among the treatment groups, indicating that siCD115 
does not change HSPC proliferation rates (Fig. 3 A). Because 
BrdU may act as a mitogen (Takizawa et al., 2011), we also 
used a CFSE dilution assay to measure LSK proliferation 
(Fig. 3 B). For this assay, we sorted LSKs from CD45.1+ mice, 
labeled them with CFSE, and transferred them into LPS-
primed CD45.2+ mice treated with either siCD115 or siCON. 
Transferred CFSE-labeled LSKs diluted the dye at similar rates 
in both treatment cohorts, indicating similar rates of LSK 
proliferation, but the total number of splenic BrdU+ HSPCs 
declined after siCD115 treatment, reflecting reduced HSPC 
retention in the splenic niche (Fig. 3 A).
understood, especially compared with the well-studied bone 
marrow niche. Understanding HSC retention factors and their 
regulation in the spleen was the purpose of this study.
Because the spleen harbors very few HSCs in the steady 
state, we investigated the splenic hematopoietic niche after 
injecting the Toll-like receptor ligand LPS to activate extra-
medullary hematopoiesis. In the bone marrow, macrophages 
are an integral part of the HSC niche (Winkler et al., 2010; 
Chow et al., 2011) and differentiation depends on the re-
ceptor for macrophage colony-stimulating factor (M-CSFR, 
CD115; Auffray et al., 2009). We thus hypothesized that splenic 
hematopoietic niche assembly also requires M-CSFR signaling. 
In line with knockout studies (Takahashi et al., 1994; Dai 
et al., 2002), in vivo knockdown of M-CSFR with nanoparticle- 
encapsulated siRNA reduced splenic macrophage numbers 
substantially. Interestingly, decreased macrophage numbers 
were associated with a reduction of splenic HSCs. Depleting 
macrophages with diphtheria toxin (DT) in CD169 iDTR 
mice reproduced the findings obtained with M-CSF–directed 
siRNA treatment, thereby indicating that macrophages have 
a key role in splenic HSC maintenance. To investigate how 
splenic macrophages retain HSCs, we measured changes in 
splenic expression of major bone marrow retention factors after 
M-CSFR silencing. Silencing M-CSFR selectively reduced 
splenic VCAM-1, and the adhesion molecule was primarily 
expressed by macrophages. Inhibiting macrophage expression of 
VCAM-1 with siRNA targeting this adhesion molecule re-
duced splenic HSPC numbers. Finally, we found that M-CSFR 
and macrophage-directed VCAM-1 silencing in mice with 
atherosclerosis mitigated blood leukocytosis and dampened in-
flammation in atherosclerotic plaques and the infarcted myocar-
dium. These data reveal the importance of VCAM-1 expression 
by splenic macrophages for extramedullary hematopoiesis and il-
lustrate the therapeutic potential of RNAi as an antiinflam-
matory that mutes emergency overproduction and provision 
of myeloid cells.
RESULTS
M-CSFR (CD5) knockdown attenuates  
LPS-induced splenomegaly
Several siRNA sequences targeting the M-CSF receptor were 
selected using in silico prediction methods (Dahlman et al., 
2014) and tested in vitro at two concentrations in M-CSFR–
expressing cells. The six best duplexes (Fig. 1 A) underwent 
further testing at seven dilutions (Fig. 1 B). The siRNA with 
the best in vitro silencing at low concentrations (siCD115; 
sense, cuAcucAAcuuucuccGAAdTsdT; anti-sense, UUC-
GGAGAAAGUUGAGuAGdTsdT) was incorporated into 
lipidoid nanoparticles (Love et al., 2010) for in vivo studies. 
These nanoparticles exhibit particular efficiency for in vivo 
silencing in monocytes and macrophages after systemic de-
livery (Leuschner et al., 2011; Novobrantseva et al., 2012; 
Majmudar et al., 2013; Courties et al., 2014) and resemble 
siRNA delivery vehicles currently used in clinical studies 
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MacDonald, 2012), we next enumerated splenic macrophages 
after silencing this receptor. Treatment with siCD115 substan-
tially reduced the numbers of splenic macrophages (Fig. 4 A). 
Because macrophages contribute to HSPC maintenance in 
the bone marrow (Winkler et al., 2010; Chow et al., 2011), 
we sought to clarify whether and how these cells might regu-
late the splenic niche. Splenic macrophages express CD169 
(Fig. 4 B) and can be efficiently depleted in CD169-iDTR 
mice (Miyake et al., 2007) via DT treatment (Fig. 4 C). Simi-
lar to the effects observed after M-CSFR silencing, this mac-
rophage depletion significantly reduced numbers of splenic 
HSCs, LSKs, and GMPs (Fig. 4 D). Bone marrow HSC and LSK 
numbers also fell significantly after macrophage depletion 
(Fig. 4 E). In contrast, HSCs, LSKs, and GMPs significantly in-
creased in the blood (Fig. 4 F), indicating HSPC mobilization 
into circulation in the absence of macrophages. Collectively, 
these data indicate that M-CSFR signaling contributes to the 
hematopoietic niche by inducing macrophage differentiation.
The observed lower splenic HSPC retention suggested 
that M-CSFR knockdown might influence the expression of 
HSPC retention factors. Indeed, siCD115 treatment signifi-
cantly reduced mRNA levels of the major retention factors 
in the bone marrow, including CXCL12, vascular cell adhe-
sion molecule-1 (VCAM-1), angiopoietin, and stem cell fac-
tor (SCF; Fig. 3 C). Yet in the spleen, VCAM-1 was the only 
retention factor significantly reduced by siCD115 treatment 
(Fig. 3 D). Reducing these retention factors may favor pro-
genitor release into the blood (Winkler et al., 2010). Accord-
ingly, we found that M-CSFR knockdown increased the 
numbers of circulating LSKs by threefold (Fig. 3 E), indicating 
increased HSPC departure from their niches in the absence of 
M-CSFR signaling.
Macrophages’ role in the splenic niche
Because M-CSFR regulates macrophage differentiation, 
survival, and proliferation (Auffray et al., 2009; Hume and 
Figure . M-CSFR (CD5) knockdown 
reduces LPS-induced splenomegaly. (A) In 
vitro screening for siRNA inhibitors of CD115 
mRNA (n = 3 per group). (B) Concentration 
dependence of the six best siRNAs against 
CD115 mRNA (n = 3). (C) Experimental design. 
LPS-treated mice were injected with siRNA 
against CD115 (siCD115) or control siRNA 
with an irrelevant sequence (siCON), or left 
uninjected. (D) CD115 mRNA levels in FACS-
isolated monocytes/macrophages (n = 4–6). 
(E) CD115 expression on monocytes/macro-
phages by flow cytometry (n = 6–8 per 
group). (F) Body (n = 3–5) and (G) spleen 
weight of naive and treated mice (n = 3–10). 
(H) Total splenocyte count of naive and 
treated mice (n = 4–9 per group). (I) Serum 
IFN- levels measured by ELISA (n = 3–8). 
Flow cytometric plots (J) and quantification 
(K) of monocytes and Ly-6chigh monocytes in 
blood after siRNA treatment (n = 3–5). Data 
were pooled from 2–5 independent experi-
ments and are mean ± SEM. Significance was 
determined by Mann-Whitney test or one-
way ANOVA. **, P < 0.01; ***, P < 0.001.
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To investigate if splenic VCAM-1+ macrophages are 
monocyte-derived or sourced from local progenitors, we in-
duced parabiosis of GFP+ and GFP mice (Fig. 5 H). After 
6 wk of parabiosis, very few (<1%) VCAM-1+ macrophages 
were derived from the parabiont, i.e., from circulatory mono-
cytes (Fig. 5, H and I). These data indicate that splenic VCAM-1+  
macrophages arise from tissue progenitors rather than the bone 
marrow, in line with previously published data on splenic macro-
phages (Yona et al., 2013).
Our data suggest that splenic macrophages retain progeni-
tors via expression of the adhesion molecule VCAM-1. To 
test this hypothesis directly, we formulated siRNA that tar-
gets VCAM-1 within macrophage-avid lipidoid nanoparticles 
(sense, AcuGGGuuGAcuuucAGGudTsdT; anti-sense, ACC-
UGAAAGUcAACCcAGUdTsdT). This treatment, which 
limited VCAM-1 protein concentrations in macrophages but 
not in endothelial cells (Fig. 6 A), reduced splenic progenitor 
retention (Fig. 6 B).  In contrast, numbers of HSCs, LSKs, 
and GMPs increased significantly in the circulation (Fig. 6 C), 
Splenic resident macrophages retain HSCs via VCAM-
Because VCAM-1 was the only retention factor that changed 
in the spleen after M-CSFR knockdown (Fig. 3 D), we in-
vestigated which splenocytes express VCAM-1. We found that 
splenic macrophages (Ulyanova et al., 2005) and endothelial 
cells express VCAM-1 at high levels (Fig. 5, A and B). We 
next tested whether splenic HSCs reside close to VCAM-1– 
expressing cells. Toward this end, we transferred GFP+  
HSPCs (LSKs) into LPS-primed mice and imaged splenic sec-
tions 3 d later. Transferred GFP+ progenitors localized in nu-
merous splenic locations and formed colonies in the red pulp, 
indicating their proliferation (Fig. 5 C). GFP+ colonies lo-
calized near VCAM-1+ macrophages (Fig. 5 D). Numerous 
GFP+ cells closely contacted VCAM-1–expressing macro-
phages in the splenic red pulp (Fig. 5, E and F; and Video 1). 
Indeed, 44.4 ± 3.7% of GFP+ cells lay in direct contact with 
or <1 µm distant from VCAM-1+ macrophages (Fig. 5 G). 
Another 49.4 ± 3.1% of the HSPCs resided within 1–10 µm 
of VCAM-1+ macrophages.
Figure . Reduced HSC and progenitor levels in the spleen and bone marrow after CD5 knockdown. (A) Gating for LSKs, HSCs, and GMPs. FACS 
enumeration of HSCs, LSKs, and GMPs in the spleen (B) and bone marrow (C) after siRNA treatment (n = 3–19). Quantification of apoptotic bone marrow 
LSKs and HSCs (D) and splenic LSKs (E) after CD115 knockdown (n = 4–5). Data were pooled from 4 (B and C) experiments. (D and E) One of two indepen-
dent experiments. Data are mean ± SEM. Statistical significance was determined by one-way ANOVA. **, P < 0.01; ***, P < 0.001.
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knockdown in macrophages (Fig. 6 D), pointing to retention 
mechanisms that compensate for reduced VCAM-1 levels 
in the bone marrow. Reduced splenic HSC retention may 
indicating mobilization of these cells into the blood after 
VCAM-1 knockdown in macrophages. In the bone marrow, 
HSPC numbers did not change significantly after VCAM-1 
Figure . Release of hematopoietic stem and progenitor cells into blood after CD5 knockdown. (A) BrdU+ LSKs, HSCs, and GMPs (top). Quantifi-
cation of BrdU+ cell % (middle). (bottom) Total BrdU+ LSKs, HSCs, and GMPs in the spleen after siRNA treatment (n = 3). (B) CFSE dilution of transferred 
LSKs (n = 3). (C) mRNA levels of HSC retention factors in (C) bone marrow and (D) spleen (n = 5–6). (E) LSKs in blood after siRNA treatment (n = 4–12). 
Data were pooled from at least two independent experiments. A and B depict one of two independent experiments. Data are mean ± SEM. Statistical sig-
nificance was determined by one-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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leukocytes that binds with VCAM-1 on activated endothelial 
cells (Elices et al., 1990), resulting in recruitment of inflam-
matory cells to sites of inflammation. Similarly, VCAM-1 
expressed by splenic macrophages may bind with VLA-4 ex-
pressed by HSCs (Williams et al., 1991). To investigate an inter-
action of VCAM-1 with VLA-4 in this setting, we transferred 
GFP+ HSPCs into LPS-treated mice after VLA-4 neutralization 
attenuate LPS-induced myelopoiesis. To test this hypothesis, we 
enumerated myeloid cells and monocytes in the blood (Fig. 6 E) 
and spleen (Fig. 6 F) and found that VCAM-1 knockdown sig-
nificantly reduced myeloid cell and monocyte numbers. Col-
lectively, these data demonstrate a requirement for VCAM-1 
expression by splenic macrophages for maintaining the or-
gan’s hematopoietic niche. VLA-4 is an integrin expressed by 
Figure . Macrophages maintain splenic 
HSCs. (A) Gating for splenic macrophages 
(top). Plots for macrophages in respective 
groups (bottom; n = 3–10). (B) Histogram for 
CD169 expression on splenic macrophages.  
(C) Macrophage depletion in CD169 iDTR 
mice. Plots show depletion of splenic macro-
phages after diphtheria toxin (DT) treatment. 
LSKs, HSCs, and GMPs in the spleen (D) and 
bone marrow (E) of CD169 iDTR mice after de-
pletion (n = 5–10). (F) LSKs, HSCs, and GMPs in 
the blood of PBS and DT-treated mice (n = 5–9).  
Data were pooled from 2–4 independent ex-
periments and are shown as mean ± SEM. 
Significance was determined by Mann-Whitney 
test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 5. Splenic HSPCs reside near VCAM-+ macrophages. (A) Gating for endothelial cells. CD45.2 CD31high ICAM-2high cells were considered as 
endothelial cells. (B) VCAM-1 expression on splenic endothelial cell and leukocytes by FACS. (C) Cluster of GFP+ cells in the splenic red pulp 3 d after GFP+ 
HSPC transfer into wild-type mouse. Bar, 15 µm. (D) Cluster of GFP+ cells (green) near VCAM-1+ macrophages (red). Bar, 20 µm. (E) GFP+ cells (green) in 
close contact with VCAM-1+ (red) macrophages (F4/80+, blue) in the spleen. Bar, 5 µm. (F) 3D image of interaction between a GFP+ cell and a VCAM-1+ 
macrophage. (G) Fraction of GFP+ cells within indicated distance from VCAM-1+ macrophages (n = 5). (H) We induced parabiosis of GFP+ and GFP mice. 
After 6 wk of parabiosis, the spleens of GFP wild-type mice were analyzed for chimerism (GFP+ cells) using flow cytometry (H) and immunofluorescence 
microscopy (I; n = 3). Bar, 10 µm. Data were pooled from two independent experiments. Data are mean ± SEM. Significance was determined by one-way 
ANOVA and Mann-Whitney test. *, P < 0.05; ***, P < 0.01.
with an antibody. We found that this blocking antibody sig-
nificantly decreased splenic HSPC retention (Fig. 6 G).
M-CSFR knockdown reduces inflammation  
in atherosclerotic plaque
Previous studies revealed that splenic myelopoiesis provides 
inflammatory monocytes to atherosclerotic plaque (Swirski 
et al., 2007; Murphy et al., 2011; Robbins et al., 2012) and 
that, after experimental MI, splenic leukocyte overproduc-
tion accelerates progression of atherosclerosis (Dutta et al., 
2012). A recent clinical trial indicated that similar mecha-
nisms may exist in humans; 18F-FDG PET/CT showed in-
creased metabolic activity in the spleens of patients with acute 
coronary syndrome (Kim et al., 2014). We thus investigated 
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atherosclerosis. ApoE/ mice fed a high fat diet received 
either siCD115 or siCON, as outlined in Fig. 7 A. In these 
mice, M-CSFR knockdown reduced splenic HSC and LSK 
whether blocking splenic leukocyte overproduction with 
siCD115, which we found to disrupt the hematopoietic niche, 
would reduce systemic inflammatory activity in mice with 
Figure 6. Macrophages retain splenic HSCs via VCAM-. (A) Flow cytometric plots showing VCAM-1 expression on splenic endothelial cells and 
macrophages after VCAM-1 knockdown. Flow cytometric plots show percentage of LSKs, HSCs, and GMPs in the spleen (B) and blood (C) of mice treated 
with siRNA against VCAM-1 (siVCAM-1) or control siRNA (siCON). Levels of LSKs, HSCs, and GMPs in the spleen (B), blood (C), and bone marrow (D; n = 8–10). 
Myeloid cells and monocytes in the blood (E) and spleen (F) after siVCAM-1 treatment in LPS-challenged mice (n = 4). (G) Reduced HSPC retention  
in the spleen after VLA-4 neutralization (n = 4–5). Two independent experiments were performed. Data are mean ± SEM. Significance was determined  
by Mann-Whitney test. *, P < 0.05; **, P < 0.01.
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In accordance with reduced monocyte accumulation, plaque 
size, and necrotic core area decreased, and fibrous cap thick-
ness increased in aortic root lesions of siCD115-treated mice 
(Fig. 7 E).
levels by 4- and 12-fold, respectively (Fig. 7 B), leading 
to much lower blood monocyte counts (Fig. 7 C). In the 
aorta, siCD115 treatment reduced the numbers of inflamma-
tory myeloid cells, monocytes, and macrophages (Fig. 7 D). 
Figure . CD5 knockdown reduces inflammation in atherosclerosis. (A) Experimental design. (B) Enumeration of LSKs and HSCs in the spleens of 
ApoE/ mice after CD115 knockdown. Representative FACS plots show percentage of monocytes in the blood (C), and macrophages and monocytes in the 
aorta (D) in ApoE/ mice treated with either control or CD115 siRNA. The bar graphs show levels of monocytes and Ly-6chigh monocytes in the blood (C) and 
macrophages and monocytes in the aorta (D) after CD115 knockdown (n = 4–5 per group). (E) Representative images showing Masson staining of the aortic 
root. The bar graphs depict quantification of total plaque size, fibrous cap thickness, and necrotic core area (n = 5 per group). Experiments were performed in 
duplicate. Bar, 30 µm. All data are shown as mean ± SEM. Statistical significance was determined by Mann-Whitney test. *, P < 0.05; **, P < 0.01.
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Figure . CD5 knockdown reduces inflammation in the infarct after coronary ligation. (A) Experimental design. (B) Myeloid cells, macro-
phages and monocytes in the infarct (n = 3–7). (C) Histological quantification of Ly-6G and CD11b staining in the infarct (n = 5). Bar, 100 µm. (D) Circu-
lating myeloid cells on day 4 after MI (n = 5). Data were pooled from 3 (B) and 2 (C&D) independent experiments. Data are mean ± SEM. Significance was 
determined by Mann-Whitney test and one-way ANOVA. *, P < 0.05, **, P < 0.01.
M-CSFR and VCAM- knockdown reduces myocardial 
inflammation after ischemic injury
Coronary occlusion leads to inflammation in the infarcted 
myocardium (Swirski and Nahrendorf, 2013). To a large 
extent, infarct macrophages derive from the spleen (Swirski 
et al., 2009; Leuschner et al., 2012). Leukocyte oversupply or 
disturbed resolution of inflammation in the heart inhibits the 
infarct healing process, leading to aggravated left ventricular 
remodeling and heart failure (Nahrendorf et al., 2007; Panizzi 
et al., 2010). Although these preclinical observations likely 
apply to patients after MI (Tsujioka et al., 2009), no therapy 
targeting post-MI leukocyte oversupply to the heart has 
improved outcomes to date. We thus investigated whether 
silencing M-CSFR decreases inflammation in the ischemic 
heart. To this end, we treated mice with either siCD115 or 
siCON after coronary ligation (Fig. 8 A). Indeed, siCD115 
treatment reduced numbers of myeloid cells, macrophages, 
and monocytes in the infarcting myocardium 4 d after coro-
nary ligation (Fig. 8 B). Likewise, histologically examined in-
farct tissue harvested on day 4 after coronary ligation showed 
significantly reduced Ly-6G and CD11b+ cells after siCD115 
treatment (Fig. 8 C). Consistent with this, siCD115-treated 
mice had lower levels of myeloid cells and monocytes in the 
blood on day 4 after MI (Fig. 8 D).
Next, we investigated the effect of VCAM-1 knockdown in 
macrophages on day 4 after myocardial infarction. siVCAM-1 
treatment significantly reduced myeloid cell, monocyte, and 
macrophage numbers in the infarct (Fig. 9, A and B). Of note, 
VCAM-1 knockdown did not alter proliferation and apopto-
sis of infarct macrophages (Fig. 9 C), indicating reduced sup-
ply of monocytes after the treatment. Consistent with this notion, 
we found significantly reduced myeloid cell and monocyte 
numbers in the blood (Fig. 9 D), bone marrow (Fig. 9 E). and 
spleen (Fig. 9 F).
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levels of macrophage retention and egress cues netrin-1 (van 
Gils et al., 2012) and CCR7 (Trogan et al., 2006). VCAM-1 
knockdown did not significantly change their expression 
(Fig. 10 F). This treatment reduced LSK and HSC numbers in 
the spleen (Fig. 10 G), thereby confirming that, in the setting 
of atherosclerosis, splenic macrophages retain HSCs via VCAM-1. 
Numbers of Ly-6chigh monocytes in the spleen (Fig. 10 H) 
and blood (Fig. 10 I) fell. VCAM-1 silencing in macrophages 
significantly decreased plaque size and necrotic cores in the 
aortic root (Fig. 10 J). However, blood cholesterol levels were 
unchanged (Fig. 10 K).
DISCUSSION
Patients with myocardial infarction exhibit high leukocyte 
counts in the blood, inflamed arterial wall, and infarcted 
myocardium. Exaggerated inflammation in the heart, com-
mon in atherosclerotic individuals, promotes left ventricular 
dilation and heart failure. Extramedullary hematopoiesis, which 
contributes to leukocyte oversupply at sites of inflammation, 
occurs in systemic inflammatory conditions such as athero-
sclerosis (Murphy et al., 2011; Robbins et al., 2012) and after 
myocardial infarction (Leuschner et al., 2012). Hence, uncover-
ing the pathways leading to extramedullary leukocyte production 
VCAM- knockdown in macrophages reduces  
inflammation in atherosclerosis
Because macrophages retain splenic HSCs through VCAM-1, 
and macrophage-directed VCAM-1 knockdown reduces LPS-
induced myelopoiesis (Fig. 6), we hypothesized that VCAM-1 
knockdown in macrophages will reduce high fat diet–induced 
splenic myelopoiesis and decrease inflammation in atherosclerotic 
plaques. When we treated ApoE/ mice with macrophage-
avid nanoparticles delivering siRNA directed at VCAM-1, 
macrophage and monocyte levels in the aorta fell (Fig. 10 A). 
To investigate if proliferation and apoptosis of atherosclerotic 
plaque macrophages depend on VCAM-1, we quantified lesion 
macrophage proliferation and apoptosis in ApoE/ mice 
using flow cytometry after 3 wk of siRNA treatment. We did 
not find a significant difference in the fraction of macro-
phages in sub-G0 phase (apoptotic cells) and S–G2–M phase 
(proliferating cells) between the groups (Fig. 10, B and C). 
Additionally, we stained aortic root sections for Ki-67 (pro-
liferation) and TUNEL (apoptosis) along with CD68. Immuno-
fluorescence histology confirmed that lesion macrophage 
apoptosis (Fig. 10 D) and proliferation (Fig. 10 E) do not 
change after treatment with siVCAM-1. To investigate if mac-
rophage exit is inhibited by VCAM-1, we quantified mRNA 
Figure 9. siVCAM- treatment reduces inflammation 
after coronary ligation in C5/Bl6 wild type mice.  
Lin CD11b+ infarct myeloid cells, monocytes and macro-
phages by flow cytometry (A) and CD11b+ infarct area  
quantified by immunohistochemistry (B; n = 4–5). The  
scale bar denotes 100 µm. Quantification of proliferating  
and apoptotic (C) macrophages in the infarct (n = 4–5 per 
group). LinCD11b+ myeloid cells and monocytes in  
(D) blood, (E) bone marrow, and (F) spleen (n = 4–5).  
This figure shows data from one of two independent experi-
ments. Data are mean ± SEM. Significance was determined  
by Mann-Whitney test. *, P < 0.05.
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as observed, for example, in the growing uterus of a pregnant 
mouse (Tagliani et al., 2011) and in peritoneal macrophages 
(Rosas et al., 2014). Moreover, M-CSF improves tissue mac-
rophage survival by reducing apoptosis (Shaposhnik et al., 
2010). During atherogenesis, vascular endothelial cells and 
smooth muscle cells can produce M-CSF (Clinton et al., 1992), 
and M-CSF–deficient op/op mice have dramatically reduced 
atherosclerotic plaques (Qiao et al., 1997; Rajavashisth et al., 
1998). Our data imply that M-CSF signaling also plays a role 
in splenic leukocyte production. Because M-CSFR knock-
down also affected the bone marrow, our data do not provide 
information on the relative contribution of the spleen versus 
bone marrow contribution to the inflammatory response after 
may reveal therapeutic avenues to mitigate disease-promoting 
leukocytosis. Although hematopoiesis in the bone marrow has 
been studied extensively, splenic hematopoiesis remains poorly 
understood. In the current study, we report that VCAM-1+ 
macrophages are essential for splenic myelopoiesis and that 
M-CSFR signaling maintains the spleen’s hematopoietic niche. 
VCAM-1–expressing macrophages retain HSCs in the splenic 
red pulp, promote extramedullary hematopoiesis, increase 
systemic levels of inflammatory leukocytes and consequently 
augment inflammation in atherosclerotic plaques.
Differentiation of monocytes to macrophages depends on 
M-CSFR signaling (Auffray et al., 2009). Local M-CSF signal-
ing may also regulate tissue-resident macrophage proliferation, 
Figure 0. VCAM- knockdown in macrophages reduces inflammation in atherosclerosis. ApoE/ mice on high fat diet were injected with con-
trol siRNA (siCON) or VCAM-1–targeting siRNA (siVCAM-1) for 3 wk. (A) Macrophages and monocytes in the aorta (n = 5–6). Apoptosis and proliferation 
(B–E) of plaque macrophages by flow cytometry (B and C) and immunofluorescence (D and E; n = 5). (F) mRNA of netrin-1 and CCR7 in the aortic root  
(n = 4–5). (G) LSK and HSC levels in the spleen of siCON and siVCAM-1-treated ApoE/ mice (n = 5). Monocyte and inflammatory (Ly-6chigh) monocyte 
levels in the spleen (H) and blood (I; n = 5–6). (J) Masson staining of the aortic root showing plaque size and necrotic core area (n = 5). Bar, 30 µm.  
(K) Blood cholesterol in ApoE/ mice (n = 6). Data were pooled from at least two experiments and are shown as mean ± SEM. Significance was deter-
mined by Mann-Whitney test. *, P < 0.05; **, P < 0.01.
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Despite growing evidence of the importance of inflam-
mation in atherosclerosis and heart failure, specific antiin-
flammatory therapy has yet to be implemented in the clinic. 
Ongoing trials explore whether antiinflammatory therapeu-
tics, such as anti-IL1–neutralizing antibodies (CANTOS, 
NCT01327846) and methotrexate (CIRT, NCT01594333) 
reduce ischemic complications and death in patients with 
atherosclerosis. In addition to biologicals or small molecule 
drugs, RNAi may therapeutically interfere with the life cycles 
of inflammatory leukocytes that drive atherosclerosis progres-
sion and complication. Recent progress in RNAi delivery 
has led to clinical trials (Coelho et al., 2013) and enabled leu-
kocyte silencing in rodents and primates (Novobrantseva 
et al., 2012). The 70-nm particles used in the current study of 
siRNA delivery to macrophages were identified in large-
scale screens (Love et al., 2010), are rapidly synthesized from 
four components, and are similar to safe materials advancing 
through clinical trials. Our data indicate that RNAi targeting 
of hematopoiesis could reduce systemic inflammation by 
curtailing leukocyte overproduction. Silencing M-CSFR ex-
pression disrupted the splenic hematopoietic niche assembly, 
potentially allowing for decisive antiinflammatory interven-
tion in individuals with vulnerable plaques or shortly after 
myocardial infarction. Currently, this approach would lend 
itself to short-term, systemic, parenteral delivery rather than 
sustained oral therapy. Longer therapeutic courses might com-
promise the salutary functions of M-CSF signaling and mac-
rophages in host defenses. Because the siRNA delivery in our 
study was systemic and therefore not limited to splenic cells, 
we are unable to define to what precise degree the observed 
therapeutic effects derive from silencing in the spleen. Likely, 
monocyte differentiation in the bone marrow or at the sites 
of inflammation, i.e., the heart and the arterial wall, also con-
tributed to lower macrophage numbers. Yet, the parallel and 
profound reduction of monocytes in the circulation and in-
flamed tissue indicates that lowering the systemic supply of 
inflammatory cells played a major role in reducing inflamma-
tion in the target tissue.
In conclusion, this study identifies a novel role for signaling 
through the M-CSFR in the genesis of splenic myelopoiesis. 
Interfering with this receptor inhibits macrophage functions 
in the splenic hematopoietic niche. These cells express VCAM-1 
to retain HSPCs in the splenic red pulp. Interrupting this path-
way with myeloid-directed in vivo RNAi, by silencing 
either M-CSFR or VCAM-1, enables HSPCs to escape from 
niches into blood and substantially reduces circulating mono-
cytes. Ours is a first study on how RNAi affects hematopoiesis. 
Finally, this intervention decreases inflammatory cell num-
bers in atherosclerotic plaque and in the ischemic myocar-
dium, illustrating an innovative approach to treating patients 
with atherosclerosis.
MATERIALS AND METHODS
Animal strains and surgical procedures. C57BL/6J, B6. SJL-Ptprca 
Pepcb/BoyJ (CD45.1), and B6.129P2-Apoetm1Unc/J (ApoE/) mice were 
purchased from The Jackson Laboratory. ApoE/ mice consumed a 
MI or LPS challenge, but previous data suggest that the 
splenic contribution to the infarct myeloid population is sub-
stantial (Leuschner et al., 2012). Previous studies showed 
nanoparticle uptake was highest in macrophages but not 
strictly limited to these cells; therefore, the described mecha-
nisms may not be exclusive. Because macrophage turnover in 
atherosclerotic plaque (Robbins et al., 2013) and in acute MI 
may be rapid (Leuschner et al., 2012), therapeutically target-
ing the cell’s supply by silencing M-CSFR may be a viable 
way to dampen inflammation in cardiovascular disease. Because 
human atheromata express M-CSFR, such an intervention 
might also directly attenuate inflammation at the plaque level 
(Salomon et al., 1992).
In accordance with mRNA array data on red pulp mac-
rophages, we found these cells express high levels of VCAM-1 
and are located in direct proximity to hematopoietic progen-
itor clusters. HSCs express the VCAM-1 ligand VLA-4 and 
rely on VCAM-1–VLA-4 interaction to anchor themselves 
in hematopoietic niches (Williams et al., 1991; Dutta et al., 
2012). This type of cell–cell interaction is common in the 
spleen, which also retains marginal zone B cells (Lu and 
Cyster, 2002) and innate response activator B cells (Rauch 
et al., 2012). The latter protect against sepsis via GM-CSF 
production in the splenic red pulp. Interestingly, GM-CSF 
expands splenic monocyte production in the setting of ath-
erosclerosis (Robbins et al., 2012; Wang et al., 2014). Our 
current study reveals that VCAM-1+ red pulp macrophages 
play a central role in maintaining splenic hematopoiesis.
Early after ischemic injury, increased angiotensin-II con-
centrations mobilize cells from the splenic monocyte reser-
voir, which contributes 50% of leukocytes to the infarct. 
Later, the spleen continues to supply myeloid cells to the 
ischemic as well as the remote myocardium, now relying on 
IL-1 and SCF signaling to enhance splenic monocyte pro-
duction (Dutta et al., 2012). Hematopoietic activity in the 
spleen follows the recruitment of bone marrow HSPCs, 
which circulate in higher numbers after MI in mice (Dutta 
et al., 2012) and in patients (Massa et al., 2005; Assmus et al., 
2012). The relocation of HSPCs from the murine bone mar-
row to the spleen accelerates production of inflammatory 
myeloid cells, exacerbating preexisting atherosclerosis (Dutta 
et al., 2012). HSPC retention in hematopoietic tissue in the 
bone marrow and the spleen (Williams et al., 1991; Scott 
et al., 2003; Dutta et al., 2012) relies at least partially on the 
integrin VLA-4, a ligand for VCAM-1, which we report to 
be expressed by splenic macrophages. Even without an acute 
inflammatory trigger, such as MI, splenic myelopoiesis oc-
curs in mice with chronic atherosclerosis (Robbins et al., 
2012). In ApoE/ mice on a high fat diet, HSPCs differen-
tiate into monocytes in the spleen, a process that depends on 
GM-CSF and IL-3 (Wang et al., 2014). These monocytes then 
enter the circulation and migrate to atherosclerotic plaques. In 
the vessel wall, the cells and their progeny secrete inflammatory 
cytokines, give rise to reactive oxygen species, and produce 
proteases, all of which may render atherosclerotic plaques vul-
nerable to rupture (Moore and Tabas, 2011).
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For hematopoietic stem and progenitor cell staining, we used biotin-
conjugated antibodies against lineage markers CD11b (clone M1/70), CD11c 
(clone N418), and IL7R (clone A7R34) in addition to the lineage antibod-
ies used for leukocyte staining. This was followed by a secondary staining 
with antibodies against c-Kit (clone 2B8), Sca-1 (clone D7), CD16/32 
(clone 2.4G2), CD34 (clone RAM34), CD115 (clone AFS98), CD150 (9D1), 
and CD48 (HM48-1).
HSC proliferation assays. Mice were injected with BrdU 24 h before 
organ collection, and intracellular BrdU staining was performed using BrdU 
flow kits (BD). For CFSE dilution assay, sorted LSKs were stained with CFSE 
(Invitrogen) according to manufacturer’s protocol and injected into B6 mice 
treated with LPS and either siCON or siCD115. BrdU incorporation and 
CFSE dilution in hematopoietic stem and progenitor cells were measured by 
an LSRII.
HSC apoptosis assay. 5,000,000 bone marrow cells or splenocytes were 
cultured in 1 ml of DMEM and camptothecin (20 µM) for 3 h to induce 
apoptosis. Apoptotic HSCs were stained with Annexin V/dead cell apoptosis 
kit (Invitrogen) and quantified by flow cytometry.
VLA-4 neutralization. Mice were injected i.v. with 200 µg of either anti–
mouse VLA-4 (BioXCell) or control rat IgG2b (BioXCell) 2 d after LPS in-
jection. About 300,000 lineage c-kit+ Sca-1+ cells sorted from GFP+ mice 
were adoptively transferred i.v. on the day of VLA-4 injection.
Total blood cholesterol measurement and ELISA. Blood was col-
lected via cardiac puncture in Eppendorf tubes without anticoagulant. Blood 
was kept at room temperature for 2 h and spun down at 4°C for 10 min 
to separate serum. Serum was stored at 80°C, and total cholesterol was 
measured using an enzymatic colorimetric assay (Cholesterol E; Wako). We 
used Quantikine Colorimetric Sandwich ELISA kit (R&D Systems) to mea-
sure serum IFN- levels.
FACS. Bones were harvested, including all long bones and the spine. Single-
cell suspensions were prepared by grinding bones with a pestle and mortar 
and passing the cells through 40-µm filters. The cells were stained with bio-
tinylated antibodies against lineage markers for hematopoietic stem and pro-
genitor cells, as described above, and then incubated with streptavidin 
MicroBeads (Miltenyi Biotec). Lineage+ cells were depleted using MACS 
columns (Miltenyi Biotec). Lin cells were stained with antibodies for 
hematopoietic stem and progenitor cells as described above. LSKs were sorted 
using a FACSAria IIu cell sorter (BD).
RNA extraction and quantification. RNA was extracted using PicoPure 
RNA isolation kit (Applied Biosystems) and eluted in a total volume of 10 µl. 
RNA was quantified using Nanodrop, and one microgram of mRNA was 
used to generate complimentary DNA (cDNA) using a high capacity RNA 
to cDNA kit (Applied Biosystems). Target genes were quantified using TaqMan 
gene expression assays (Applied Biosystems).
Histology. For histological analysis, aortas and hearts were embedded in 
OCT compound (Sakura Finetek), and fresh-frozen serial 6 µm thick sec-
tions were prepared. Masson Trichrome staining was performed according 
to the manufacturer’s instructions (Sigma-Aldrich) to assess plaque size, 
fibrous cap thickness and necrotic core. Immunohistochemistry was per-
formed using Ly-6G (1A8, BioLegend) and CD11b (M1/70, BD) anti-
bodies, biotinylated anti-rat IgG antibody (Vector Laboratories Inc.) and 
VECTASTAIN ABC kit (Vector Laboratories). The reaction was visualized 
using a 3-amino-9-ethylcarbazole (AEC) substrate (Dako), and all sections 
were counterstained with Harris hematoxylin solution (Sigma-Aldrich). The 
slides were scanned using Nanozoomer 2.0RS (Hamamatsu), and staining 
was quantified in 5 high power fields per mouse, using semiautomated 
thresholding in IPLab, and expressed as percentage of positive area.
high-cholesterol diet (Harlan Teklad; 0.2% total cholesterol) for 10 wk be-
fore the experiments. CD169-iDTR mice were gifts from M. Tanaka (Insti-
tute of Physical and Chemical Research Center for Allergy and Immunology, 
Yokohama, Japan). CD169-iDTR litter mates were used as control. For 
other strains, appropriate control mice were purchased from Jackson Labora-
tory. All animal experiments were approved by Massachusetts General Hos-
pital’s Institutional Animal Care and Use Committee.
To induce myocardial infarction, mice were intubated and ventilated 
with 2% isoflurane, and then underwent thoracotomy in the fourth left 
intercostal space. The left coronary artery was permanently ligated with a 
monofilament nylon 8–0 suture. The thorax was closed with a 5–0 suture.
siRNA formulation and in-vitro screening. siRNAs duplexes were 
generated to target the CSFR1 (M-CSFR) transcript. Single-strand RNAs 
were designed and produced at Alnylam Pharmaceuticals as described previ-
ously (Frank-Kamenetsky et al., 2008). The NIH 3T3 cell line was trans-
fected with siRNAs targeting M-CSFR or nontargeting control siRNA 
complexed with Lipofectamine RNAiMAX Transfection Reagent (Invitro-
gen) at 0.5 and 5 nM final concentrations. Cells were harvested 24 h after 
transfection, and expression levels of M-CSFR mRNA were quantified 
by the branched DNA QuantiGene 2.0 assay (Affymetrix) using mouse 
M-CSFR–specific probes. Dose response was performed on the best siRNA 
duplexes with an siRNA, with the best siRNA having an EC50 of 10 pM. 
This M-CSFR–targeted siRNA (siCD115) was scaled up for in vivo studies 
and has the following sequence: cuAcucAAcuuucuccGAAdTsdT (sense), 
UUCGGAGAAAGUUGAGuAGdTsdT antisense), wherein lower case let-
ters identify 2OMe modified nucleotides. VCAM-1–targeting siRNA was 
identified similarly, except C2C12 cells were used for siRNA screening and 
qRT-PCR using TaqMan primers, and probes were mRNA quantification. 
The VCAM-1–specific duplex selected for in vivo studies has the following 
sequence: AcuGGGuuGAcuuucAGGudTsdT (sense), ACCUGAAAGU-
cAACCcAGUdTsdT (antisense). M-CSFR and VCAM1 targeting siRNAs 
were independently encapsulated into nanoparticle formulations as described 
previously (Akinc et al., 2008; Leuschner et al., 2011).
Treatment protocol. C57BL/6 mice were treated with 10 µg of LPS for 
three consecutive days before tissue harvesting on the fourth day. siRNA 
against either M-CSFR or VCAM-1 was administered i.v. at 0.5 mg/kg 
body weight on the first and third day. To test efficacy of the siRNA after 
myocardial infarction, siRNA against either M-CSFR or VCAM-1 was in-
jected i.v. at 0.5 mg/kg body weight on the day of MI and 2 d after MI. 
ApoE/ mice were injected with the siRNA three times per week for 3 wk. 
CD169-iDTR mice were injected with DT i.v. at 10 µg/kg body weight on 
the first and fourth days before analysis on the seventh day.
Organ harvesting and tissue processing. Cardiac puncture was per-
formed to draw blood with an insulin syringe in 50 mM EDTA (Sigma- 
Aldrich). Red blood cell lysis was performed with 1× RBC lysis buffer 
(BioLegend) according to the manufacturer’s protocol. Hearts were minced 
and digested in 450 U/ml collagenase I, 125 U/ml collagenase XI, 60 U/ml 
DNase I, and 60 U/ml hyaluronidase (Sigma-Aldrich) at 37°C at 750 rpm 
for 1 h. Cells were washed in 10 ml FACS buffer (PBS with 0.5% bovine 
serum albumin and 1% fetal bovine serum) and filtered through 40-µm mesh 
to obtain single-cell suspension. Spleens were minced in FACS buffer and 
passed through 40-µm filters, followed by red blood cell lysis in the filtrate. 
Femurs were flushed with ice-cold FACS buffer.
Flow cytometry. Single cell suspensions (300 µl in FACS buffer) were 
stained with a cocktail of antibodies against lineage markers (CD90 [clone 
53–2.1], B220 [clone RA3-6B2], CD49b [clone DX5], NK1.1 [clone 
PK136], Ly-6G [clone 1A8], and Ter-119 [clone TER-119]). After 30 min 
of staining, the cells were washed in FACS buffer and stained with antibodies 
against leukocyte markers (CD11b (clone M1/70), CD11c (clone HL3), 
F4/80 (clone BM8), and Ly6C (clone AL-21)).
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Immunofluorescence microcopy. 3 d after priming with LPS, the spleen 
was harvested and fixed by immersion in a 4% PFA PBS solution. Fixed tis-
sues were cryoprotected in a 30% sucrose, 0.02% sodium azide, PBS solution 
at 4°C. Tissues were embedded and frozen in tissue freezing media (Leica) and 
then sectioned in a 20°C cryostat (Leica) at a thickness of 10 and 25 µm.
The tissue sections were stained with an anti–VCAM-1 antibody (sc-
1504; Santa Cruz Biotechnology) and an anti-F4/80 (14–4801; eBioscience) 
antibody followed by a Cy3 donkey anti–rabbit and Cy5 donkey anti–rat 
IgG (Jackson ImmunoResearch Laboratories). Sections were mounted in 
Vectashield + DAPI mounting media.
Microscopic images were acquired with an Eclipse 90i epifluorescence 
microscope (Nikon). Digital image files were post-processed with Nikon Imag-
ing Software Elements, Volocity 6 (Perkin Elmer), ImageJ, and IP laboratory.
For Ki-67 immunofluorescence imaging, heart tissue sections were stained 
with FITC Ki-67 (clone SP6, dilution 1:25; Abcam). To detect apoptotic car-
diac macrophages, TUNEL reagents (DeadEnd Fluorometric TUNEL System; 
Promega) were used according to the manufacturer’s protocol.
Online supplemental material. Video 1 shows interaction between HSPCs 
and VCAM-1+ macrophages in the spleen. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20141642/DC1.
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